340B health care providers are hopeful that U.S. health secretary Xavier Becerra will sanction six drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO Ted Slafsky writes this week in his latest column for Omnicell.
Slafsky devotes much of his April 13 column to recapping the many twists and turns in federal courts from coast to coast over the boundaries of federal power to make the drug companies offer 340B pricing on their products, without regard to how those drugs are dispensed.
340B health care providers are hopeful that U.S. health secretary Xavier Becerra will sanction six drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO Ted Slafsky writes this week in his latest column for Omnicell.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
